Cards Acccepted | 6% OFF Crypto | 3rd Party Testing | FREE Worldwide Shipping $400+
Menu
Cart
tirzepatide lyophilized peptide vial
Tirzepatide 5-60mg - 10 Vial Box - Image 2
lyophilized peptide vial box (blue cap)
Tirzepatide certificate of analysis
Tirzepatide HPLC

Tirzepatide 5-60mg – 10 Vial Box

$225.00 – $1,260.00

Buy tirzepatide 5, 10, 15, 20, 30, 40, or 60 mg (one 10-vial box). All orders are shipped wholesale in unbranded packaging. Worldwide 7 – 14 day shipping to the USA, UK, AUS & NZ.

Bulk discounts
QuantityBulk DiscountPrice
25%$213.75
3-57%$209.25
6-1010%$202.50
SKU: TIR10Category:

Description

Tirzepatide is a peptide that helps regulate blood sugar levels and support weight management by mimicking natural hormones that control appetite and glucose balance. It’s commonly used to promote weight loss and improve glycemic control in type 2 diabetes patients. Tirzepatide is the generic peptide version of Mounjaro and Zepbound.

Minimum order quantity: one box (10 vials x 5-60mg). Photo for illustration purposes only.

Additional information

Purity

≥99.0%

Molar Mass

4813.527 g·mol

Molecular Formula

C₂₂₅H₃₄₈N₄₈O₆₈

Sequence

H-Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Lys(Eicosanedioyl-isoGlu-PEG2-PEG2)-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2

Strength

5MG, 10MG, 15MG, 20MG, 30MG, 40MG, 60MG

  1. Min, Thinzar, and Stephen C. Bain. "The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: the SURPASS clinical trials." Diabetes Therapy 12.1 (2021): 143-157.
  2. Jastreboff, Ania M., et al. "Tirzepatide once weekly for the treatment of obesity." New England Journal of Medicine 387.3 (2022): 205-216.
  3. Frías, Juan P., et al. "Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes." New England Journal of Medicine 385.6 (2021): 503-515.
  4. Syed, Yahiya Y. "Tirzepatide: first approval." Drugs 82.11 (2022): 1213-1220.
  5. Rosenstock, Julio, et al. "Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial." The Lancet 398.10295 (2021): 143-155.
  6. Rosenstock, Julio, et al. "Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial." The Lancet 398.10295 (2021): 143-155.
  7. Chavda, Vivek P., et al. "Tirzepatide, a new era of dual-targeted treatment for diabetes and obesity: a mini-review." Molecules 27.13 (2022): 4315.

Tirzepatide CoA 2024

Tirzepatide HPLC

3rd Party Testing (5mg Vial)

Related products